Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group. Marty FM, et al. Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Epub 2011 Mar 21. Lancet Infect Dis. 2011. PMID: 21414843 Clinical Trial.
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.
Blackmon A, Afkhami M, Yang D, Mokhtari S, Samara Y, Pourhassan H, Ball B, Salhotra A, Agrawal V, Sandhu K, Desai A, Otoukesh S, Arslan S, Amanam I, Koller P, Tinajero J, Aribi A, Aldoss I, Becker P, Artz A, Ali H, Stein A, Smith E, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Al Malki MM. Blackmon A, et al. Among authors: pullarkat v. Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491-0. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39695333
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, Panse J, Pullarkat V, Röth A, Shammo J, Terriou L, Weitz I, Yermilov I, Gibbs S, Broder M, Beenhouwer D, Kuter D. Dingli D, et al. Among authors: pullarkat v. Hematology. 2024 Dec;29(1):2329030. doi: 10.1080/16078454.2024.2329030. Epub 2024 Mar 21. Hematology. 2024. PMID: 39665683 Free article.
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, Aribi A, Karaoglu DA, Pourhassan H, Koller P, Ali H, Blackmon A, Otoukesh S, Sandhu K, Ball B, Artz AS, Al Malki MM, Salhotra A, Tinajero J, Gu Z, Lagman I, Velasquez M, Dang J, Becker PS, Afkhami M, Ghoda L, Stock W, Forman SJ, Stein A, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: pullarkat v. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.286427. Online ahead of print. Haematologica. 2024. PMID: 39506897 Free article.
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
Tinajero J, Xu S, Ngo D, Li S, Palmer J, Nguyen T, Stein A, Koller P, Agrawal V, Pourhassan H, Murphy L, Forman S, Douer D, Marcucci G, Pullarkat V, Aldoss I. Tinajero J, et al. Among authors: pullarkat v. Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19880. Online ahead of print. Br J Haematol. 2024. PMID: 39505575
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Roloff GW, et al. Among authors: pullarkat v. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Online ahead of print. J Clin Oncol. 2024. PMID: 39418622
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission.
Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. Rahman ZA, et al. Among authors: pullarkat v. Transplant Cell Ther. 2024 Dec;30(12):1197-1205. doi: 10.1016/j.jtct.2024.09.020. Epub 2024 Sep 26. Transplant Cell Ther. 2024. PMID: 39332807
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.
Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, Blackmon A, Agrawal V, Pourhassan H, Amanam I, Arslan S, Otoukesh S, Sandhu K, Aldoss I, Ali H, Salhotra A, Al Malki MM, Artz A, Becker P, Smith E, Stein A, Marcucci G, Forman SJ, Curtin P, Nakamura R, Pullarkat V. Desai A, et al. Among authors: pullarkat v. Leuk Res. 2024 Oct;145:107565. doi: 10.1016/j.leukres.2024.107565. Epub 2024 Aug 25. Leuk Res. 2024. PMID: 39208597
219 results